- Home
- EPAM vs INCY Comparison
EPAM vs INCY Comparison
Compare EPAM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPAM
- INCY
- Stock Information
- Founded
- EPAM 1993
- INCY 1991
- Country
- EPAM United States
- INCY United States
- Employees
- EPAM N/A
- INCY N/A
- Industry
- EPAM EDP Services
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- EPAM Technology
- INCY Health Care
- Exchange
- EPAM Nasdaq
- INCY Nasdaq
- Market Cap
- EPAM 8.2B
- INCY 13.4B
- IPO Year
- EPAM 2012
- INCY 1993
- Fundamental
- Price
- EPAM $179.83
- INCY $59.73
- Analyst Decision
- EPAM Buy
- INCY Hold
- Analyst Count
- EPAM 17
- INCY 20
- Target Price
- EPAM $230.63
- INCY $73.06
- AVG Volume (30 Days)
- EPAM 699.3K
- INCY 1.9M
- Earning Date
- EPAM 05-08-2025
- INCY 04-29-2025
- Dividend Yield
- EPAM N/A
- INCY N/A
- EPS Growth
- EPAM N/A
- INCY N/A
- EPS
- EPAM 7.15
- INCY 0.10
- Revenue
- EPAM $4,864,167,000.00
- INCY $4,413,226,000.00
- Revenue This Year
- EPAM $13.81
- INCY $12.28
- Revenue Next Year
- EPAM $8.44
- INCY $9.20
- P/E Ratio
- EPAM $25.12
- INCY $542.94
- Revenue Growth
- EPAM 4.72
- INCY 17.13
- 52 Week Low
- EPAM $138.15
- INCY $52.81
- 52 Week High
- EPAM $269.00
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- EPAM 66.53
- INCY 46.72
- Support Level
- EPAM $156.21
- INCY $58.04
- Resistance Level
- EPAM $162.87
- INCY $62.87
- Average True Range (ATR)
- EPAM 4.60
- INCY 1.82
- MACD
- EPAM 3.50
- INCY 0.33
- Stochastic Oscillator
- EPAM 86.41
- INCY 53.41
About EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm that offers platform engineering, software development, and consulting services. EPAM's largest market is North America, which represents approximately 60% of revenue. Offerings span assisting companies with new technologies, such as artificial intelligence, virtual reality, and robotics.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.